Future research is needed to study the use of obesity treatments other than AOM liraglutide and AOM semaglutide, including lifestyle interventions and use of other GLP-1 and non-GLP-1 anti-obesity medications
This is where things slowed down
As for topical application, the studies are also promising
doi:10.1016/s2213-8587(21)00174-1
Endorsed by #ATTD and several leading diabetes organizations, the consensus provides practical recommendations to support clinicians in the safe and effective use of these therapies, including guidance on insulin adjustments, risk mitigation, and clinical decision-making
What I really like is that it also focuses on microbiome wellness with next-generation probiotics, which I believe is why my digestion and overall gut health feel better too